Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 32Head & Neck 9Gynecologic 6Thoracic 5Breast 4Tumor-Agnostic 2Other hematologic neoplasm 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 2

Interventions

Paclitaxel 162Fulvestrant 157Trastuzumab 156pembrolizumab 145Letrozole 136Carboplatin 118pertuzumab 104Capecitabine 104Cyclophosphamide 102Specimen Handling 101Anastrozole 90palbociclib 86abemaciclib 82Magnetic Resonance Spectroscopy 80exemestane 76Docetaxel 76ribociclib 74Tamoxifen 74trastuzumab deruxtecan 67Radiotherapy 62Biopsy 58Surveys and Questionnaires 55Gemcitabine 53130-nm albumin-bound paclitaxel 53olaparib 52sacituzumab govitecan 51Blood Specimen Collection 50Standard of Care 49Taxes 48eribulin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
camrelizumab × Breast × 1 year × Clear all
NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Fudan University

Phase 2 Recruiting
120 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Harbin Medical University

Phase 2 Active not recruiting
30 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07107217 2025-08-17

Camella

Blokhin's Russian Cancer Research Center

Phase 2 Not yet recruiting
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡